S. A. Klyushnikov

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf et al. · The Lancet Neurology · 2021 · 184 citations · Full text

Veterinary Medicine, Internal Medicine, Pharmacotherapy +3

Manifestation of Huntington’s disease pathology in human induced pluripotent stem cell-derived neurons

V. A. Vigont, S. A. Klyushnikov, Olga S. Lebedeva et al. · Molecular Neurodegeneration · 2016 · 153 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks

Priya S. Kishnani, Jordi Díaz‐Manera, António Toscano et al. · JAMA Neurology · 2023 · 55 citations · Full text

Life Sciences, Internal Medicine, Pharmacotherapy +8

STIM2 Mediates Excessive Store-Operated Calcium Entry in Patient-Specific iPSC-Derived Neurons Modeling a Juvenile Form of Huntington's Disease

V. A. Vigont, Dmitriy A. Grekhnev, Olga S. Lebedeva et al. · Frontiers in Cell and Developmental Biology · 2021 · 41 citations · Full text

Life Sciences, Neurology, Neuroscience +16

Alpha–theta border EEG abnormalities in preclinical Huntington's disease

S. A. Klyushnikov, Natalya Abramycheva, Daria Malina et al. · Journal of the Neurological Sciences · 2014 · 36 citations

Life Sciences, Neurology, Neuroscience +8